Elliott Management Invests Over $1 Billion in BioMarin Pharmaceutical Amid Strategic Leadership Transition and Strong Pipeline Momentum
In November 2023, Elliott Investment Management (hereinafter referred to as “Elliott”), one of the world’s largest activist hedge funds, injected more than $1 billion into the biotechnology company BioMarin Pharmaceutical (hereinafter referred to as “BioMarin”), and the two parties signed a cooperation and information-sharing agreement. On the day Reuters published the report, the company’s stock price rose by approximately 12%.
BioMarin, founded in 1997 and headquartered in California, USA, is a biopharmaceutical company dedicated to developing therapies for rare diseases. In July 1999, it successfully completed its initial public offering (IPO) on the NASDAQ, raising $67.3 million.
That very month, as BioMarin secured investment from Elliott, it had just announced the appointment of Alexander Hardy, former CEO of Genentech (a Roche subsidiary), as its new CEO. Luca Issi, an analyst at RBC Capital Markets, noted that while the substantial investment was predictable given BioMarin’s operational performance, the timing—coinciding with the new CEO’s recent appointment—was unexpected.
Since GEN began compiling its Top 10 M&A deals in the biopharmaceutical sector in 2013, BioMarin has consistently ranked among the top. FierceBiotech also included BioMarin in its “Top 10 Potential Acquisition Targets in Biopharma for 2022.” Furthermore, BioMarin has been the subject of merger rumors with pharmaceutical giants such as Roche, Amgen, and Gilead, solidifying its status as one of the ten most sought-after acquisition targets.
BioMarin’s former CEO, JJ Bienaimé, retired after 18 years in office. The new CEO, Alexander, holds a bachelor’s degree from the University of Cambridge and an MBA from the Ross School of Business at the University of Michigan. He also serves as a member of the Board of Directors of the Pharmaceutical Research and Manufacturers of America (PhRMA). With over 30 years of experience in the healthcare and biotechnology industries, including nearly two decades at Genentech and Roche, Alexander has been serving as CEO of Genentech, a member of the Roche Group, since 2019. During this challenging period, he oversaw the successful launch of 10 innovative drugs and led the company to achieve breakthrough progress in multiple therapeutic areas, including oncology, neuroscience, hemophilia, and ophthalmology.
Prior to this, Alexander held key positions at Roche and Genentech, including Head of Global Product Strategy, Head of Asia-Pacific, and Co-Chair of the Late-Stage Portfolio Committee. In these roles, he was primarily responsible for dynamically adjusting development strategies for products in late-stage development, as well as communicating with internal and external partners regarding candidate molecules. Before joining Genentech and Roche, he also held positions at Novartis, PathoGenesis, and GlaxoSmithKline.
Alexander Hardy (Image source: BioMarin official website)
During his tenure, Alexander mentioned that he could see the huge potential of BioMarin, and in the future ROCTAVIAN™, VOXZOGO®We are highly confident in the product portfolio and the realization of value from its underlying early-stage drug pipeline.
ExcludingAlexander’s potential involvement: The company’s financial health is undoubtedly a key determinant in attracting Elliott to take an equity stake. According to BioMarin’s financial data,In 2023, the company’s total revenue reached $2.42 billion (a year-on-year increase of 15%, or 20% on a constant-currency basis), with total revenue projected to achieve double-digit growth in 2024.
(Image source:BioMarin Official Website)
Specific analysis,Total revenue in the fourth quarter of 2023 was $646.2 million, representing a 20% increase compared to the same period in 2022.。
(Image source:BioMarin Official Website)
The growth in total revenue was primarily attributable to drugs for achondroplasia.VOXZOGO®growth in sales volume. Because inU.S. Food and Drug Administration ((FDA) Approved VOXZOGO in October®For use in children of all ages with open growth plates after treatment,Prescription Volume Increases for U.S. Children Under 5 Years of Age
Another reason for the increase in sales isVIMIZIM®Product Revenue Increase(Large Government Orders), but due to the loss of market exclusivity, competition from generic drugs is intense,KUVAN®Product revenue declined,Therefore,partially offset this growth.It was precisely due to generic drugs that the company communicated with the National Health Commission in June 2022 and no longerKUVAN®（Product Name“Kewang”) to renew the Import Drug Registration Certificate. According to data from the NMPA website, Kewang’s Drug Registration Certificate expired on March 31, 2023.
withCompared with the same period in 2022, GAAP net income increased by $200,000 to $20.4 million in the fourth quarter of 2023.
(Image source:BioMarin Official Website)
The primary reasons for the increase in net profit were higher revenue, and the company’sSeverance costs related to the organizational restructuring announced in the fourth quarter of 2022ofdecrease. However, due to R&D supporting early-stage research and clinical activities (R&D) project expenditures increased, asset impairment charges, corporate governance and leadership transition costs, supportROCTAVIAN™Sales and administrative expenses related to commercial launch (SG&A Expenses IncreaseWait, partially offsetting the aforementioned growth.
The size of the R&D pipeline is a key indicator for assessing the development trajectory of innovative pharmaceutical companies, while the market potential of drugs under development provides a pathway for revenue growth.BioMarin has an extensive portfolio across therapeutic areas including musculoskeletal and metabolic disorders, non-oncology hematology, cardiovascular diseases, and the central nervous system, with nearly 20 drug candidates in its pipeline.
BioMarin Drug Pipeline (Image source: BioMarin official website)
In addition to what was mentioned in the financial statement analysisExcluding certain BioMarin products, the company has focused on the rare disease sector and launched a total of eight products in the more than 25 years since its inception., respectivelyROCTAVIAN™、VOXZOGO®、PALYNZIQ®、BRINEURA®、VIMIZIM®、KUVAN®、NAGLAZYME®andALDURAZYME®. The following section will focus on the first two products.
·ROCTAVIAN™（valoctocogene roxaparvovec-rvox）
ROCTAVIAN™ is a gene therapy indicated for the treatment of adults with severe hemophilia A (congenital factor VIII [FVIII] deficiency, with FVIII activity <1 IU/dL) who test negative for antibodies to adeno-associated virus serotype 5 (AAV5) using an FDA-approved test. ROCTAVIAN™ uses an AAV5 viral vector (modified to exclude viral DNA) to deliver the gene encoding coagulation factor VIII.
ROCTAVIAN™ (Image source: BioMarin official website)
Hemophilia is a genetic disorder caused by gene mutations. Current treatments primarily involve injections of recombinant or plasma-derived clotting factor concentrates. However, the cost of lifelong treatment is substantial, and the development of inhibitory antibodies may compromise therapeutic efficacy. In contrast, gene therapy offers a different approach by restoring the function of the mutated gene, enabling severePatients with hemophilia A are able to produce factor VIII (FVIII) endogenously, which facilitates blood coagulation and prevents or reduces bleeding episodes at the source.Patients may require only a single treatment, enabling hepatocytes to sustainably express coagulation factors.VIII, thereby eliminating the need for long-term prophylactic coagulation factor injections.
In August 2022, the European Commission (EC) approved the marketing authorization of BioMarin’s groundbreaking therapy for hemophilia A, ROCTAVIAN™, marking the world’s first gene therapy for hemophilia A. In June 2023, ROCTAVIAN™ received FDA approval for market launch.
·VOXZOGO®
VOXZOGO®Shi Shouthe only therapy approved to enhance linear growth in children with achondroplasia and open growth plates，is a once-daily injectionC-type natriuretic peptide (CNP) analogs. UseVOXZOGO®children need to undergo regular check-ups,Based on physical development statusDosage Adjustment，Upon confirmationItsDiscontinue use when growth potential is exhausted and the growth plates have closed.
VOXZOGO®(Image source: BioMarin official website)
August 2021, VOXZOGO®Approved for marketing in the European Union for patients aged two years and older with achondroplasia and open growth plates.In the same yearNovember,FDA Accelerated ApprovalVOXZOGO®used in the United StatesPatients aged 5 years and older with achondroplasia and open growth plates, and grantedBioMarinandVOXZOGO®Priority Review Voucher for Rare Pediatric Diseases Related to Accelerated Approval (PRV）, in recognition ofThe company’s outstanding contributions to the research and development of new drugs for rare diseases.In October 2023, the FDA approved VOXZOGO.®Supplemental New Drug Application for Injectable Products(sNDA), expanding the indication to all children with open growth plates across all age groups. In the United States and the European Union, VOXZOGO®Both have been granted orphan drug designation for the treatment of achondroplasia (ODD）。
VOXZOGO®of2022 projected sales were $90–115 million, while actual sales reached $169.1 million; VOXZOGO®ofThe projected sales for 2023 were estimated at $330–380 million, while the final sales reached $470 million, significantly exceeding expectations and leading to production capacity shortages due to a surge in demand.
BioMarin undoubtedly possesses the capabilities and advantages to develop first-in-class and best-in-class proprietary pipelines.
Alexander Hardy, President and Chief Executive Officer of BioMarin, stated that in 2024 the company intends to leverageVOXZOGO®the opportunity to continue contributing toROCTAVIAN™ establishes global market access channels and prudently prioritizes R&D candidates with the greatest potential impact.
In December 2021, Jiutian Bio, an emerging biotechnology company in China, entered into a collaboration with BioMarin to jointly research and develop novel adeno-associated virus (AAV)-based gene therapies for the treatment of hereditary cardiovascular diseases. As a leader in the field of gene therapy, particularly in novel viral vectors, Jiutian Bio possesses a fully integrated AAV gene therapy research, development, and manufacturing platform.
UnlikeTraditional small-molecule and macromolecular drugs, cell and gene therapies (Cell and Gene Therapy,CGT）with relativeDifferentiated Treatment Approaches。Gene Therapyregarded as a“A revolutionary therapy that offers a one-and-done solution,”Mainly Applied toTumors and Various Hereditary Rare DiseasesTherapeutic area. It far surpasses traditional therapies in terms of treatment cost and efficacy, making it one of the most promising directions for development in the biopharmaceutical field.
According toASGCT(Annual Meeting of the American Society of Gene and Cell Therapy)statistics, as of2024 yearsQ4, global R&DCGT Pipeline Reaches3951, showing a quarter-on-quarter upward trend. In gene therapy,Among RNA therapies and cell therapies, gene therapy pipelines account for the largest share, reaching as high as 53%.
Therapies in Development by CategoryFigure (Image source: ASGCT official website)
According toSullivanEstimation, GlobalThe market size of CGT therapies is expected to reach $30.54 billion in 2025, corresponding to a CAGR of 71.2% from 2020 to 2025. December 2023，The FDA released a draft guidance titled “Assuring Potency for Cell and Gene Therapy Products”, the draft also mentionsThe Growing Trend of Rapid Clinical Development for CGT Products。
CGTFor patients, it has“The advantage of ‘immediate therapeutic effect,’ but for innovative pharmaceutical companies, it has”High Production Costs、Complex Process Flowand the disadvantage of long preparation cycles，ThereforeThe CGT Industry'sCDMOthe degree of dependence onHigh. According toJ.P. Morgan statistics,Compared with traditional biologics,CGTwith higherOutsourcing Penetration Rate(EstimatedMore than65%). in the global field of gene therapyCDMO as shown below.
Gene TherapyCDMO Industry Landscape (Data Source: VBInsight)
According to incomplete statistics from VBInsight,From 2009 to 2023, a total of 565 financing transactions occurred in the global primary market for gene therapy, with cumulative funding amounting to approximately USD 24.269 billion. In 2023, multiple projects in China’s gene therapy drug development sector secured substantial financing, indicating that the “appeal” of gene therapy has been recognized, while its potential remains to be fully realized.
Ranking of Financing Amounts in the Field of Gene Therapy Drug DevelopmentTop 5 Projects
(Image source: "“2023 Annual White Paper on Innovative Drugs and Supply Chain Innovation”